These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 19558720)
1. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. Horger M; Lauer UM; Schraml C; Berg CP; Koppenhöfer U; Claussen CD; Gregor M; Bitzer M BMC Cancer; 2009 Jun; 9():208. PubMed ID: 19558720 [TBL] [Abstract][Full Text] [Related]
2. Sorafenib in hepatocellular carcinoma. Josephs DH; Ross PJ Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487 [TBL] [Abstract][Full Text] [Related]
3. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Yau T; Chan P; Ng KK; Chok SH; Cheung TT; Fan ST; Poon RT Cancer; 2009 Jan; 115(2):428-36. PubMed ID: 19107763 [TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma. Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Sakata K; Matsugaki S; Kajiwara M; Fukuizumi K; Tajiri N; Matsukuma N; Sakai T; Ono N; Yano Y; Koga H; Kurogi J; Takata A; Sumie S; Satani M; Yamada S; Niizeki T; Aino H; Iwamoto H; Torimura T; Sata M Oncology; 2013; 84(2):108-14. PubMed ID: 23147476 [TBL] [Abstract][Full Text] [Related]
5. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. Lee JH; Park JY; Kim DY; Ahn SH; Han KH; Seo HJ; Lee JD; Choi HJ Liver Int; 2011 Sep; 31(8):1144-9. PubMed ID: 21745288 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201 [TBL] [Abstract][Full Text] [Related]
7. Target therapy for hepatocellular carcinoma: is sorafenib for everybody? Daniele B; Di Maio M J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813 [No Abstract] [Full Text] [Related]
8. Evolution of systemic therapy of advanced hepatocellular carcinoma. Yau T; Chan P; Epstein R; Poon RT World J Gastroenterol; 2008 Nov; 14(42):6437-41. PubMed ID: 19030192 [TBL] [Abstract][Full Text] [Related]
9. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764 [TBL] [Abstract][Full Text] [Related]
10. Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. Spira D; Fenchel M; Lauer UM; Claussen CD; Gregor M; Bitzer M; Horger M Acad Radiol; 2011 Jan; 18(1):89-96. PubMed ID: 20926315 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497 [TBL] [Abstract][Full Text] [Related]
12. Advanced hepatocellular carcinoma. Review of targeted molecular drugs. Alves RC; Alves D; Guz B; Matos C; Viana M; Harriz M; Terrabuio D; Kondo M; Gampel O; Polletti P Ann Hepatol; 2011; 10(1):21-7. PubMed ID: 21301005 [TBL] [Abstract][Full Text] [Related]
13. Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study. Lee S; Yoon SH; Park JY; Kim DY; Ahn SH; Han KH; Choi HJ Invest New Drugs; 2012 Jun; 30(3):1150-7. PubMed ID: 21249514 [TBL] [Abstract][Full Text] [Related]
14. Clinical response after sorafenib for hepatocellular carcinoma in elderly patients: a report of two cases. Spada F; Squadroni M; Lorizzo K; Farris A; Fazio N Tumori; 2012; 98(2):53e-56e. PubMed ID: 22678005 [TBL] [Abstract][Full Text] [Related]
15. Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation. Kim R; Aucejo F J Gastrointest Cancer; 2011 Mar; 42(1):50-3. PubMed ID: 20714941 [TBL] [Abstract][Full Text] [Related]
16. Sorafenib for liver cancer: the horizon broadens. Johnson P; Billingham L Lancet Oncol; 2009 Jan; 10(1):4-5. PubMed ID: 19111238 [No Abstract] [Full Text] [Related]
17. MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib. Kang HC; Tan KS; Keefe SM; Heitjan DF; Siegelman ES; Flaherty KT; O'Dwyer PJ; Rosen MA AJR Am J Roentgenol; 2013 Jan; 200(1):120-6. PubMed ID: 23255750 [TBL] [Abstract][Full Text] [Related]
18. Complete response for advanced liver cancer during sorafenib therapy: case report. Sacco R; Bargellini I; Gianluigi G; Bertini M; Bozzi E; Altomare E; Battaglia V; Romano A; Bertoni M; Capria A; Bresci G; Bartolozzi C BMC Gastroenterol; 2011 Jan; 11():4. PubMed ID: 21241463 [TBL] [Abstract][Full Text] [Related]
19. Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study. Hidaka H; Nakazawa T; Kaneko T; Minamino T; Takada J; Tanaka Y; Okuwaki Y; Watanabe M; Shibuya A; Koizumi W J Gastroenterol; 2012 Sep; 47(9):1030-5. PubMed ID: 22402773 [TBL] [Abstract][Full Text] [Related]
20. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study. Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Tajiri N; Satani M; Niizeki T; Aino H; Okamura S; Iwamoto H; Shimose S; Shirono T; Koga H; Torimura T; Cancer Med; 2015 Dec; 4(12):1836-43. PubMed ID: 26471348 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]